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The p53 tumor suppressor is activated in response to a variety of cellular stress signals, although specific
in vivo signals that trigger tumor suppression are unknown. In mouse thymocytes, where p53 inactivation leads
to tumorigenesis, several observations suggest that V(D)J recombination of T-cell receptor (TCR) loci could
provide a DNA damage signal triggering p53-dependent apoptosis and tumor suppression. Inactivation of p53
would allow V(D)J driven mutation of additional cancer genes, facilitating tumorigenesis. Here, we show that
mice with a p53 deficiency in thymocytes and unable to carry out V(D)J recombination are not impaired in the
development of thymoma. Recombination-activating gene (RAG) deficiencies were introduced into both p532/2
mice and TgTDN transgenic mice, a strain in which 100% of the mice develop thymoma due to thymocyte-
specific inactivation of p53 by a simian virus 40 T-antigen variant. V(D)J recombination was dispensable for
tumorigenesis since thymomas developed with or without the RAG-1 or RAG-2 gene, although some delay was
observed. When V(D)J recombination was suppressed by expression of rearranged TCR transgenes, 100% of
the TgTDN mice developed thymoma, surprisingly with reduced latency. Further introduction of a RAG
deficiency into these mice had no impact on the timing or frequency of tumorigenesis. Finally, karyotype and
chromosome painting analyses showed no evidence for TCR gene translocations in p53-deficient thymomas,
although abundant aneuploidy involving frequent duplication of certain chromosomes was present. Thus,
contrary to the current hypothesis, these studies indicate that signals other than V(D)J recombination promote
p53 tumor suppression in thymocytes and that the mechanism of tumorigenesis is distinct from TCR trans-
location oncogene activation.
The p53 tumor suppressor is activated in response to a
variety of cellular stress signals, including DNA damage. Its
ability to facilitate growth arrest and/or cell death in response
to such signals is believed to be the basis for its tumor sup-
pressor function (see references 5, 16, 22, and 27 for reviews).
However, specific in vivo signals that trigger tumor suppression
have not been identified. Sixty to eighty percent of the spon-
taneous malignancies in p53-deficient mice are thymic lympho-
mas (13, 17), indicating that natural thymocyte events signal
p53 tumor suppression. The favored hypothesis is that flawed
T-cell receptor (TCR) gene recombination events signal p53-
dependent elimination of damaged cells (15, 17, 24, 28). p53
inactivation would thus facilitate the survival of cells carrying
tumorigenic mutations. This hypothesis is consistent with sev-
eral observations, including that (i) double-strand DNA breaks
(DSBs) trigger p53 responses (29), (ii) p53 is required for
DNA damage-induced thymocyte apoptosis (11, 23), (iii) thy-
mic lymphomas induced by p53 deficiency are clonal, indicat-
ing that additional tumorigenic events are required (38), and
(iv) in scid mice, which accumulate V(D)J breaks, lymphoid
malignancies are accelerated by p53 deficiency (15, 28). Since
V(D)J translocations are frequently associated with oncogene
activation in human and mouse lymphoid tumors, it is reason-
able to suspect that these events may be involved in tumori-
genesis in the absence of p53-mediated surveillance.
V(D)J recombination affects TCR and immunoglobulin (Ig)
DNA rearrangement in developing T and B cells to generate a
variety of antigen receptor specificities. Normally this process
occurs during specific stages of T- and B-cell differentiation to
yield a single productive rearrangement per cell for each
polypeptide component of the receptor. The initiating event in
V(D)J recombination, the generation of specific DSBs, re-
quires two recombination activating genes (RAGs), RAG-1
and RAG-2 (9, 31). Mice deficient in either of these genes fail
to undergo V(D)J recombination and are immunodeficient
due to the lack of mature T and B cells (25, 37). Thus, these
mice provide an approach for assessing the role of V(D)J
recombination in thymomagenesis associated with p53 defi-
ciency. Here we examine the impact of inactivating V(D)J
recombination on tumorigenesis by introducing RAG deficien-
cies and/or rearranged TCR transgenes into mice with a
thymocyte p53 deficiency. Additionally, we analyze the chro-
mosomes of p53-deficient thymomas for evidence of TCR
translocations and other aberrations.
MATERIALS AND METHODS
Mice. RAG-12/2 (C57BL/6J-sv/129), scid/scid (C57BL/6J), TgN(TcrLCMV)
(B6D2), and p532/2 (C57BL/6J) mice were from Jackson Laboratory, and RAG-
22/2 mice (129, SvEv) were from Taconic Laboratory. TgTDN mice (B6D2),
previously referred to as TgLST1135, abundantly express the dl1135 simian virus
40 (SV40) large T antigen (T-Ag) in thymocytes under the regulation of the
lymphotropic papovavirus transcriptional signals (38). Although low levels of the
transgene are also expressed in B cells, only thymic lymphoma develops in these
mice (38). The dl1135 protein (referred to here as TDN) binds p53 and the pRB
family proteins and inactivates p53 in vivo (10, 24). TDN is defective in trans-
formation of cultured cells due to a deletion (residues 17 to 27) that inactivates
an N-terminal transformation function (32). The TDN transgene harbors a de-
letion in the small t antigen splice donor site and does not express SV40 small t
antigen. With the exception of scid mice, PCR assays of tail DNA were used to
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screen mouse genotypes as previously described (17, 38) or according to Jackson
Laboratory [,http://www.jax.org/resources/documents/imr/protocols/TgN(Tcr-
LCMV).html.]. RAG-1 alleles were identified by using two primer pairs: for
RAG-1 wild type, RAG-1F (59-CCA GTA GAT ACC ATT GCG AAG AGG-39)
and RAG-1B (59-CAC GTT CTG TGA ACC ATG CTC TAT C-39); and for
RAG-1 knockout, RAG-1B and Neo-R (59-CCG CTT CCA TTG CTC AGC
GG-39). PCR conditions were 35 cycles of 30 s at 94°C, 1 min at 59°C, and 1 min
at 72°C. RAG-2 alleles were identified by using two primer pairs: for RAG-2 wild
type, RAG-2A (59-GGG AGG ACA CTC ACT TGC CAG TA-39) and RAG-2B
(59-AGT CAG GAG TCT CCA TCT CAC TGA-39); and for RAG-2 knockout,
RAG-2B and Neo-2 (59-AGG TGA GAT GAC AGG AGA TC-39). PCR con-
ditions were 35 cycles of 1 min at 94°C, 1 min at 55°C, and 1 min at 72°C. The
scid mice were screened by using enzyme-linked immunosorbent assay (ELISA)
detection of serum IgM, which is absent in scid mice (14).
To generate TgTDN or p532/2/RAG2/2 and TgTDN or p532/2/RAG1/2
mice, TgTDN or p532/2 mice were bred with RAG2/2 (RAG-1 or RAG-2) mice,
and F1 offspring were intercrossed. p532/2 mice were bred to C57BL scid/scid
mice, and F1 offspring were intercrossed to derive p532/2 scid/scid and p532/2
scid/wt (wild-type) animals. The latter were distinguished from p532/2 wt/wt
mice, which are both positive by ELISA, in test breeding with scid/scid mice. If
heterozygous at the scid locus, ;50% of the offspring scored negative by ELISA
(scid/scid). A similar breeding strategy was used to generate TgTDN/scid/scid and
TgTdN/scid/wt mice. To generate TgTDN/TgTcr/RAG-12/2 and TgTDN/TgTcr/
RAG-11/2 mice, TgTDN/RAG-12/2 mice were crossed to TgN(TcrLCMV)
mice, and F1 TgTDN/TgTcr/RAG-11/2 mice were further bred with TgTDN/
RAG-12/2 mice. Animals were sacrificed and necropsied upon showing dis-
tressed breathing due to extensive thymic enlargement or were autopsied upon
death. Fresh tumor samples were divided and either fixed for immunohistochem-
istry analysis or used for thymocyte isolation.
FACS analysis. Thymoma cell type was determined by fluorescence-activated
cell sorting (FACS) analysis using phycoerythrin (PE)–anti-CD90 (Thy-1.2) and
fluorescein isothiocyanate (FITC)–anti-CD45R/B220 antibodies (PharMingen),
and thymocyte distribution was determined by using FITC–anti-CD4 and PE–
anti-CD8 antibodies (PharMingen), as described previously (18). The thymocyte
proliferation index was determined by in vivo labeling with bromodeoxyuridine
(BrdU) (Boehringer Mannheim) for 1 h after intraperitoneal injection (0.1 ml/10
g of body weight), isolation of thymocytes as described previously (24, 38), and
FACS analysis with FITC–anti-BrdU antibody (Boehringer Mannheim) and
propidium iodide staining. The total thymocyte apoptotic index was determined
by FACS using a modification of the terminal deoxynucleotidyltransferase-me-
diated dUTP-biotin nick end labeling assay (Cell Death Detection kit) as rec-
ommended by Boehringer Mannheim.
Karyotype and fluorescence in situ hybridization analyses. Minced mouse
thymoma cells were harvested directly, using routine cytogenetics laboratory
procedures for preparation of metaphase chromosomes (41). Karyotypes were
determined by standard Giemsa banding techniques (36). Biotinylated mouse
whole chromosome paint probes for chromosomes 6, 13, and 14 were used as
instructed by the supplier (Oncor, Inc., Gaithersburg, Md.). These probes were
obtained from flow-sorted mouse chromosomes and were optimized to hybridize
only to target chromosomes. Hybridization to repetitive sequences was sup-
pressed by including excess mouse repetitive DNA. Biotinylated probes were
detected by incubation with rabbit antibiotin antibody, biotinylated anti-rabbit
antibody, and streptavidin-FITC. Mouse chromosomes were counterstained with
propidium iodide. Images of metaphases were captured by a charge-coupled
device camera and analyzed with Smartcapture software (Vysis Inc., Downers
Grove, Ill.).
RESULTS
Mice deficient in both RAG and p53 develop thymoma. We
introduced RAG-1 or RAG-2 deficiency into mice lacking thy-
mocyte p53 activity by using standard genetic crosses as out-
lined in Materials and Methods. Since T-cell tumorigenesis in
p532/2 mice is not fully penetrant and other complicating
tumor types develop, in most experiments we used transgenic
mice that express an SV40 T-Ag derivative, TDN, specifically in
thymocytes (see Materials and Methods). This oncoprotein
inactivates p53, and we previously showed that 100% of
TgTDN mice develop exclusively thymic lymphoma at about 5
months of age (38). Prior to 2 months of age, thymocyte dis-
tribution is normal and consists predominantly of CD4 CD8
double-positive (DP) thymocytes (38). From 2 to 5 months, the
thymus expands rapidly and consists increasingly of a single Vb
T-cell class high in cell surface CD3 and CD4 CD8 single
positive, double negative, or DP (38). This phenotype is de-
pendent on a functional T-Ag p53-binding domain (40), and
T-cell tumors are indistinguishable from those induced by
p53 gene inactivation (22a, 38). Furthermore, preneoplastic
TgTDN thymocytes are defective in irradiation-induced p53-
dependent apoptosis (24).
The high frequency and predictability of thymic lymphoma
in TgTDN mice facilitate quantitative studies on the role of
V(D)J recombination. However, in addition we generated
p532/2 mice deficient in RAG-2 to control for any unexpected
effects of TDN. If V(D)J recombination is required for T-cell
tumorigenesis in the absence of p53, inactivation of this pro-
cess would inhibit tumorigenesis. TgTDN/RAG-12/2, TgTDN/
RAG-22/2, and p532/2/RAG-22/2 mice were generated through
standard backcrosses, and the timing and frequency of thy-
moma were measured. All of the mice became ill and were
sacrificed and necropsied (Fig. 1A). Thymic lymphoma had
developed in the majority of RAG-deficient TgTDN mice, al-
though the frequency was somewhat reduced (85% in TgTDN/
RAG-12/2 mice and 83% in TgTDN/RAG-22/2 mice [Table
1]). A few mice developed lymph node tumors or had no
FIG. 1. Thymoma develops in TgTDN and p532/2 mice with altered V(D)J
recombination. Survival of mice is plotted against time. Each data point reflects
the sacrifice or death of a terminally ill mouse. Due to strain differences, litter-
mates of each cross serve as controls. Mice that did not show overt thymoma are
indicated by asterisks. (A) Effect of a RAG-deficient background on the timing
and frequency of thymomagenesis in TgTDN mice. As with TgTDN mice (38), all
of the seven TgTDN/RAG-11/2 and all of the six TgTDN/RAG-21/2 mice
developed thymoma. The shorter latency in TgTDN/RAG-21/2 mice is most
likely caused by background strain effects. Overt thymoma developed in the
majority of TgTDN/RAG-12/2 (85%, n 5 20) and TgTDN/RAG-22/2 (83%, n 5
12) mice. Three mice of the RAG-1-deficient set and two mice of the RAG-2-
deficient set showed no overt thymoma at the time of sacrifice. One TgTDN/
RAG-12/2 mouse developed a lymph node tumor, and one TgTDN/RAG-22/2
mouse had splenomegaly in addition to an enlarged thymus. No neoplasm was
detected in the other three mice, a phenotype also observed in mice with only a
RAG deficiency (not shown). Six TgTDN/RAG-22/2 mice are not included in the
survival analysis since their early death precluded assessment of thymoma. Of
these, three had lymph node tumors of an undetermined cell type. (B) Effect of
RAG-2 deficiency on p532/2 mice. Thymoma developed in 56% of the nine
p532/2/RAG-21/2 mice and in 67% of the nine p532/2/RAG-22/2 mice. The
remaining mice developed other characteristic p532/2 tumors, including sar-
coma, testicular tumors, and lymphoma (13, 17).
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obvious neoplasm (a phenotype also observed in mice with
RAG deficiency alone [see the legend to Fig. 1]). Thymoma
developed in 55% of the p532/2 RAG-21/2 mice (Fig. 1B), a
frequency lower than for TgTDN mice due to the development
of other tumor types (as previously observed). Inactivation of
V(D)J recombination did not reduce this frequency, as 67% of
p532/2 RAG-22/2 mice developed thymoma (Fig. 1B; Table
1). FACS analysis of three TgTDN/RAG-12/2 thymomas showed
that cells were CD4 CD8 DP, CD3 negative, and Vb negative,
consistent with the fact that V(D)J recombination is inactive
(data not shown). The high frequency of thymoma in p53 and
RAG-deficient mice indicates that V(D)J recombination, and
T-cell differentiation in general, is dispensable for T-cell tu-
morigenesis.
Although most RAG-deficient TgTDN mice developed thy-
moma, tumors arose more slowly or with longer latency, based
on extended survival (Fig. 1A; Table 1). All of the control
TgTDN/RAG-11/2 mice developed thymoma with a t50 (time
at which half of the animals were sacrificed or died due to overt
illness) of 165 days, similar to that previously reported for
TgTDN mice (38). The t50 for TgTDN/RAG-1
2/2 mice, how-
ever, was 238 days. Thymoma developed with reduced latency
in control TgTDN/RAG-21/2 mice (t50 5 146 days) compared
to TgTDN mice, most likely due to a background strain effect.
Relatively, in TgTDN/RAG-22/2 littermates the t50 was again
delayed (167 days), albeit to a lesser extent. A similar delay was
also observed in p532/2 RAG-22/2 mice (t50 5 180 days)
compared to p532/2 RAG-21/2 mice (t50 5 165 days; Fig. 1B,
Table 1).
V(D)J recombination is not required for T-cell tumorigen-
esis. Since RAG-deficient mice harbor fewer thymocytes and
are blocked in T-cell development (25, 37), the observed delay
and reduced frequency of thymoma may simply reflect a
smaller and/or altered target cell population rather than a
direct effect of V(D)J recombination. This could cause a dra-
matic effect, particularly when p53 is inactivated as a result of
transgene expression, which may not occur in every cell. To
circumvent these complications, T-cell development was res-
cued in TgTDN/RAG-12/2 mice by thymocyte-specific expres-
sion of rearranged TCRa and TCRb transgenes (9). Crosses
with mice harboring lymphocytic choriomeningitis virus-spe-
cific TCR transgenes [TgN(TcrLCMV)] (33) were carried out
as described in Materials and Methods. The effect of TCR
transgenes on thymomagenesis in control TgTDN/TgTcr/
RAG-11/2 mice also served as a test for the role of V(D)J
recombination, in that expression of rearranged TCR trans-
genes alone suppresses (though does not eliminate) V(D)J
recombination (42). Surprisingly, tumorigenesis was acceler-
ated in TgTDN/TgTcr/RAG-11/2 mice (t50 5 110 days) rela-
tive to TgTDN/RAG-11/2 littermates (t50 5 165 days) (Fig. 2).
Hence, suppressed V(D)J recombination provided no deter-
rent to tumorigenesis. The reason for accelerated tumor de-
velopment is unknown, but it could reflect increased target cell
numbers or altered thymocyte proliferation. In support of this
possibility, young (6-week-old) TgTDN/TgTcr/RAG-11/2 mice
had an abnormally high percentage of thymocytes in S phase
(22.9%), while nontransgenic and TgTDN S-phase thymocytes
comprised only 8.8 and 8.9%, respectively, of the total popu-
lation. Total apoptosis levels were unchanged (data not
shown).
To measure the effect of complete inactivation of V(D)J
recombination, TgTDN/TgTcr/RAG-11/2 mice were further
backcrossed to RAG-12/2 mice (see Materials and Methods).
Importantly, RAG deficiency had no impact on the timing or
frequency of tumorigenesis in TgTDN/TgTcr mice (Fig. 2). All
TgTDN/TgTcr/RAG-12/2 mice developed thymic lymphoma
within the same accelerated time frame (t50 5 101 days) as
TgTDN/TgTcr/RAG-11/2 mice. The predominant cell type in
each of three thymomas was CD4 CD8 DP, CD3 positive, and
TCRb positive. This result shows that the increased latency
and slightly reduced frequency of thymoma in RAG-deficient
TgTDN mice was not due to the absence of V(D)J recombi-
nation. Since tumorigenesis was unaffected by complete ab-
sence of V(D)J recombination in the presence of T-cell mat-
uration, the recombination process is not required for, nor
FIG. 2. Effect of TCR transgene expression on the timing and frequency of
thymomagenesis. TgTDN/TgTcr/RAG-11/2 mice (n 5 22) developed thymoma
with reduced latency compared with TgTDN/RAG-11/2 mice (n 5 9). RAG-1
deficiency (n 5 11) had no further effect. All mice developed thymoma.
TABLE 1. Summary of effect of V(D)J recombination inactivation on p53-deficient thymoma
p53







TDN RAG-11/2 Yes 100 165
TDN RAG-12/2 No 85 238
TDN RAG-21/2 Yes 100 146
TDN RAG-22/2 No 83 167
p532/2 RAG-21/2 Yes 55 165
p532/2 RAG-22/2 No 67 180
TDN RAG-11/2 TgTcr Yes 100 110
TDN TgTcr 1 RAG-12/2 Yes 100 101
TDN scid/wt Yes 93 183
TDN scid/scid No 62 210
p532/2 scid/wt Yes 60 183
p532/2 scid/scid No 0 214
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does it affect the rate of, T-cell tumorigenesis induced by p53
inactivation.
No acceleration of T-cell tumorigenesis in a scid back-
ground. Although the foregoing studies show that V(D)J re-
combination is dispensable for thymoma development, it is
possible that the recombination pathway, if present, plays a
role that may be compensated for in its absence. This possi-
bility seems unlikely given that the putative compensatory pro-
cess would not rescue V(D)J recombination and would thus
function by a different mechanism. Nonetheless, two ap-
proaches were used to test this possibility. In the first approach,
tumorigenesis rates were tested in the scid background (8). scid
mice are defective in the DNA-dependent protein kinase ac-
tivity required for rejoining of V(D)J coding DNA ends (12,
43). As a result, scid lymphocytes accumulate V(D)J-associ-
ated DSBs. Thus, although the recombination overall is inhib-
ited, the hypothesized signal to p53 would be increased. If such
breaks provide secondary cooperating mutations for tumori-
genesis in the absence of p53, thymoma development would be
accelerated in this background. Indeed, previous studies
showed that p532/2/scid mice died earlier than p532/2 litter-
mates (7, 15, 28). However, because p53 was absent from all
cells, these mice developed B-cell, as well as T-cell, lymphoma.
In TgTDN mice, exclusive analysis of thymoma is possible.
Consistent with results for the TgTDN/RAG2/2 mice, devel-
opment of thymic lymphoma was not accelerated in TgTDN/
scid mice (Fig. 3A; Table 1). Instead, tumorigenesis was
slightly delayed in these mice (t50 5 210 days) compared to
TgTDN/scid/wt mice (t50 5 183 days). To determine whether
this effect was unique to the transgenic mice, p532/2/scid
crosses were performed (Fig. 3B). Again, thymomagenesis was
clearly not accelerated. Although three of five p532/2/scid/wt
mice developed thymoma within the usual time frame (t50 5
183 days), none of the p532/2/scid/scid mice developed thy-
moma. Rather, these mice died of other causes with a t50 of 214
days (see the legend to Fig. 3). Because the number of p532/
2/scid/scid mice analyzed was small, this difference may not be
statistically significant. However, lack of thymoma acceleration
is consistent with what occurs in the TgTDN/scid/scid mice. The
difference in these experiments compared with those reported
previously is not clear but may be attributable to the difference
in scid background strains used (see Discussion). The scid-
dependent delay observed here in TgTDN mice most likely
reflects a reduced number of thymocytes as in RAG-deficient
mice. Thus, these experiments show no evidence that increased
V(D)J DSBs accelerate T-cell lymphoma development in the
absence of p53.
Chromosome analysis of p53-deficient thymomas. As an-
other test for participation of V(D)J recombination in p53-
deficient thymic lymphoma, chromosomes of TgTDN thymo-
mas were analyzed for evidence of translocations involving
TCR loci. If flawed recombination events provide the signal for
p53 tumor suppression, these events should contribute to tu-
morigenesis in the absence of p53 and would be identifiable in
tumor cells. This is a reasonable expectation since tumorigenic
translocations involving TCR or Ig genes occur in several hu-
man T- and B-cell neoplasms (20, 30, 35). Furthermore, TCR
translocations are readily observed with increased frequency in
ataxia telangiectasia (AT) lymphoid malignancies (20, 39) and
in thymomas induced by ATM (AT mutated) deficiency in
FIG. 3. Tumorigenesis is not accelerated in scid mice. The effect of the scid
mutation on the timing and frequency of thymomagenesis in TgTDN and p532/2
mice was measured as described in the legend to Fig. 1. (A) TgTDN/scid/scid
mice (n 5 29) developed thymoma with increased latency compared with their
TgTDN/scid/wt littermates (n 5 15); 93% of the TgTDN/scid/wt mice and 62% of
the TgTDN/scid/scid mice developed thymoma. One TgTDN/scid/wt mouse and
four TgTDN/scid/scid mice developed splenomegaly. No neoplasm was detected
in seven TgTDN/scid/scid mice. (B) Thymoma developed in 60% of the five
p532/2/scid/wt mice, but in none of the five p532/2/scid/scid mice. The nine
control scid/scid mice did not develop thymoma, and most remained alive for the
duration of the study. Mice without overt thymoma are indicated by asterisks.












TgTDN-1 4 (9/10); 5, 11,
and 15 (8/10)
47 40–49
TgTDN-2 15 (7/8) [t(5;?) (2/8)] 44 40–48
TgTDN-3 [t(5;5) (3/5)] 41 38–41
TgTDN-4 9 (4/5); 4 and 13
(5/5)
[t(5;5) (1/5)] 47 42–49
TgTDN-5 42 40–46
TgTDN-6 [5 (3/5)] 41 39–41




TgTDN-9 1, 3, 8, (4/5); 4, 5,
10, and 15 (5/5)
51 50–53
p532/2-1 1, 3, 4, 17, and 19
(5/5)
49 48–50
p532/2-2 4 (7/10) t(15;15) (8/10) 42 39–60
p532/2-3 [t(2;19) (5/10)] 39 39
a Trisomic chromosomes and translocations present in the majority of met-
aphases ($70%) are listed; less frequent chromosome duplications are in brack-
ets. The frequencies of the aberrations are indicated in parentheses as number of
cells with the aberration/total cell number examined. Sample TgTDN-8 con-
tained double minute chromosomes. Average chromosome numbers are
rounded to the nearest whole integer. The ranges of chromosome numbers in
individual cells are also listed.
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mice (4, 45). Evidence suggests that ATM has a role in some
p53 DNA damage-induced checkpoints (19).
Karyotypes of nine TgTDN and three p532/2 terminal thy-
momas were analyzed (Table 2). Only three tumors harbored
translocations in the majority of cells analyzed, and none of
these involved the TCR-bearing chromosomes 6, 13, and 14. In
contrast, aneuploidy, including abundant trisomy and some
tetrasomy, was frequently observed. Although any of the 20
chromosomes could be affected, trisomy of chromosome 1, 4,
5, or 15 was frequently present (Table 2). Such specificity in
chromosome aberrations may indicate the participation of on-
cogene amplification in thymoma development. Although
these data are not sufficient to address the role of any given
oncogene, several genes, including some (c-myc [2, 6], lck [1],
and scl/tal1 [3, 21]) known to play a role in T-cell tumorigen-
esis, are present on the selected chromosomes (Table 3).
To be sure that karyotype analysis did not overlook TCR
translocations not visibly detectable, we further analyzed tu-
mors by chromosome painting. Metaphase spreads from seven
FIG. 4. p53-deficient thymomas do not contain TCR translocations. Metaphase spreads were hybridized with paint probes as indicated in Materials and Methods.
(A) Chromosome 14 probe showing painting of one large chromosome illustrating t(14;14) in an ATM2/2 control thymoma. (B) The same metaphase using only a filter
for propidium iodide. (C) Trisomy 14 in a TgTDN-3 thymoma, representative of trisomy observed in several samples (Table 4). (D) Representative disomy 14 in a
TgTDN-1 thymoma. Note that the painting probes do not paint the entire chromosome because of suppression by total mouse repetitive sequences to maintain
specificity (34).
TABLE 3. Proto-oncogenes encoded by tumor-specific trisomiesa
Chromo-
some no. Proto-oncogenes
1 ...........elk4, K-ras1, L-myc2, mdm4, mybl1
4 ...........fgr, jun, lci, lck, L-myc1, lyn, mos, mpl, ski, lag, ril2, scl/tal1
5 ...........kit, gro1, L-trm3, N-myc2
15 .........myc, ril1
a Information was derived from the MRC Database of the Mammalian Ge-
netics Unit at Harwell, England (http://www.mgu.har.mrc.ac.uk/genelist/genelist-
s.html). ril1 and ril2, radiation-induced leukemia 1 and 2; lag, leukemia-associ-
ated gene.
TABLE 4. Painting analysis of TCR chromosomesa
Mouse genotype no. Aberration
TgTDN-10 ......................................................—
TgTDN-11 ......................................................16 [3]/113 [1]/114 [2]
TgTDN-12 ......................................................16 [6]/113 [3]/114 [4]
TgTDN-13 ......................................................—
TgTDN-14 ......................................................—
TgTDN-15 ......................................................16 [1]/1616 [2]/113 [3]
TgTDN-16 ......................................................16 [2]/113113 [1]
TgTDN/RAG-21/2 ........................................113 [1]/114114 [2]
TgTDN/Tcr/RAG-22/2-1..............................16 [1]/114 [1]/114114 [2]
TgTDN/Tcr/RAG-22/2-1..............................—
ATM2/2 .........................................................t(14;14) [20]
a Twenty cells for each thymoma specimen were examined by using painting
probes for chromosomes 6, 13, and 14 as described in Materials and Methods.
Shown are cells with trisomies, tetrasomies, or translocations (number of met-
aphases in brackets). No listing for a given chromosome indicates disomy. —,
samples where all 20 metaphases were disomic for each chromosome.
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TgTDN, one TgTDN/RAG-11/2, and two TgTDN/RAG-12/2
tumors were painted with whole-chromosome probes for chro-
mosomes 6, 13, and 14. None of these tumors showed evidence
of TCR translocation, while a control ATM-deficient tumor
showed a t(14;14) translocation in all cells examined (Fig. 4;
Table 4). Together with the genetic evidence described above,
these studies indicate that V(D)J recombination does not par-
ticipate significantly in p53-deficient thymomagenesis. The
chromosome analysis also suggests that the mechanism for
thymic lymphoma induction may be different for p53 deficiency
than for ATM deficiency, in which case these factors function
in distinct pathways in thymocyte tumor suppression. This no-
tion is supported by the observation that thymoma develop-
ment is more rapid in ATM2/2/p532/2 mice than in mice
harboring either single deficiency (44).
DISCUSSION
Although previous data are consistent with the hypothesis
that TCR gene recombination could be involved in p53-defi-
cient T-cell tumorigenesis, studies presented here indicate that
this process is not required. Inactivation of V(D)J recombina-
tion using RAG-deficient mice did not inhibit T-cell tumori-
genesis predisposed by p53 deficiency. This was most evident in
TgTDN/RAG-12/2 mice in which T-cell maturation was res-
cued by expression of rearranged TCRa and -b transgenes. In
that case, neither the timing nor the frequency of tumorigen-
esis was affected by the absence of V(D)J recombination rel-
ative to controls. Interestingly, expression of rearranged TCR
genes in TgTDN mice accelerated T-cell tumorigenesis. Al-
though initially surprising, the high S-phase thymocyte popu-
lation associated with TCR transgene expression could account
for this result. Neither p532/2 nor TgTDN thymocytes prolif-
erate above normal levels prior to overt thymoma, while thy-
moma cells have a high proliferative index (22a). Thus, prolif-
eration of TCR transgene-expressing thymocytes may
overcome the need for genetic events that stimulate this step in
tumorigenesis. Regardless of the reason for acceleration of
these tumors, they do not require V(D)J recombination. Thy-
moma developed in 100% of TgTDN/TgTcr mice, even though
allelic exclusion substantially suppresses recombination. More-
over, further inactivation of V(D)J recombination by RAG
deficiency had no effect on thymoma development. Recent
studies by Nacht and Jacks (27) also concluded that V(D)J
recombination was not required for p53 deficiency-induced
thymoma. Their studies showed that a RAG deficiency in the
p532/2 background did not significantly alter tumor develop-
ment in p532/2 mice.
In the absence of TCR transgene expression, RAG defi-
ciency alone caused a delay in thymoma development, al-
though these tumors occurred with a high frequency. This
effect was most dramatic in TgTDN/RAG-12/2 mice, which
lived 44% longer than controls. The effect was not as dramatic
in TgTDN/RAG-22/2 or p532/2/RAG-22/2 mice, although
these mice lived longer (14 and 9%, respectively) than controls
as well. In the study by Nacht and Jacks (27), a RAG-1 defi-
ciency did not significantly alter the survival time of p532/2
mice. Thus, the delay we observed in TgTDN/RAG-12/2 mice
may be specific to the dependence on transgene expression for
p53 inactivation. The altered thymocyte population caused by
RAG deficiency could affect the percentage of cells expressing
TDN. While we know that the majority of TgTDN thymocytes
express TDN, we did not examine the TgTDN/RAG-12/2 thy-
mocytes for TDN expression. Our experiments using TCR
transgenic mice support the conclusion that the delay in thy-
moma development was caused by the altered and/or reduced
RAG-deficient thymocyte population. Expression of rear-
ranged TCR transgenes in RAG-deficient mice is known to
rescue the defect in mature T-cell production (9), and in this
background a RAG-specific delay in tumorigenesis is not ob-
served. Since it is unlikely that expression of the TCR trans-
genes also completely alters the mechanism of thymomagen-
esis, we conclude that inactivation of V(D)J recombination has
no impact on the development of thymoma induced by p53
deficiency.
Our studies with scid mice also support the notion that
V(D)J DSBs associated with an inability to rejoin coding ends
do not promote thymoma. In the homozygous scid back-
ground, we observed no acceleration of thymoma with either
TgTDN or p532/2 mice. This result was surprising since pre-
vious reports showed that p532/2 scid/scid mice developed
accelerated lymphoid malignancies compared to p532/2 mice
(15, 28). In those studies, most mice (60 to 88%) developed
predominantly B-cell lymphoma, although some T-cell lym-
phoma was observed. Thus, a high frequency of accelerated
thymoma was not specifically observed. TgTDN mice develop
only thymoma; survival of TgTDN mice homozygous at the scid
locus is extended by 15%, and 62% of the mice develop thy-
moma. However, the difference in our study compared to pre-
vious reports was not specific to p53 inactivation by TDN, since
the p532/2 scid/scid mice in our study also showed no accel-
eration of death due to lymphoma. A plausible explanation for
the difference between studies is that the scid mutation was in
different genetic backgrounds—C.B-17 in previous studies and
C57BL/6J here. Nacht et al. showed that the genetic back-
ground significantly affected the extent of lymphoma acceler-
ation in p532/2 scid/scid mice relative to controls, with the
effect being more dramatic in a 129/Sv-C57BL6-C.B-17 back-
ground than in a C57BL6-C.B-17 background (28). The
p532/2 scid/scid mice generated in our study were entirely
C57BL6, while the TgTDN scid/scid mice were C57BL6-DBA.
In addition to having the defect in V(D)J recombination, scid
mice are defective in general DNA repair mechanisms (8, 43).
In fact, the previous reports established that a DNA damage-
inducible p53 checkpoint is intact in scid mice (7, 15, 28). Thus,
it is possible that the acceleration of lymphoma previously
observed reflects the absence of a general DNA damage check-
point not specific to V(D)J recombination and that the level of
damage, repair, or p53-independent checkpoint functions var-
ies in distinct genetic backgrounds.
In this study, we also show that TCR translocations are not
apparent in thymomas induced by a p53 deficiency. The chro-
mosome painting analysis was performed blind, and the
ATM2/2 thymoma was readily characterized as harboring a
TCR translocation. None of the other thymomas analyzed (all
of which were induced by p53 deficiency) carried a TCR trans-
location detectable by this method. Chromosome painting is
not sensitive enough to detect small deletions or insertions
(34), and so we cannot rule out that aberrant rearrangement of
TCR loci occurred at some level. However, this method readily
detected a high frequency of TCR translocations in thymomas
from ATM2/2 mice (4). Thus, if TCR aberrations are involved
in p53-deficient thymoma, the mechanism appears to be dis-
tinct from that caused by an ATM deficiency. Together with
the genetic data described above, the chromosome analysis
indicates that V(D)J recombination does not play a substantial
role in thymomagenesis induced by p53 deficiency.
The observation that V(D)J recombination is not required
for p53-deficient thymomagenesis is surprising since DNA
damage-induced apoptosis of thymocytes has been considered
the basis for tumor suppression in this cell type. Given that a
high frequency of p532/2 mice and all TgTDN mice spontane-
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ously develop thymic lymphoma, thymocytes clearly need p53
tumor suppression for normal homeostasis. Perhaps T cells are
susceptible to more general forms of DNA damage at some
developmental stages. Alternatively, it is possible that the nat-
ural p53 signal does not involve DNA damage in these cells.
Many aberrant conditions, including cell growth disruption,
oxidative stress, and altered metabolic pools, induce p53 func-
tion in other cell types (see reference 22 for a review). The
challenge now is to determine which, if any, of these conditions
contributes to p53 tumor suppression in T cells. Although p53
is not required for apoptosis associated with clonal deletion of
T cells (11, 23, 24), it could be required for apoptosis induced
by an as yet unknown stimulus. Alternatively, p53 tumor sup-
pression in thymocytes may involve a growth arrest checkpoint
function in addition to, or instead of, apoptosis. For example,
the consistent presence of aneuploidy in p53-deficient thy-
moma may indicate that loss of p53 checkpoint regulation
leading to genetic instability has a key role in this tumor type.
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